(Total Views: 556)
Posted On: 03/13/2025 5:29:16 PM
Post# of 155808
Quote:
Gilead paid $11 billion in late 2011 for the rights to market Sovaldi, an amount it totally recouped in its first year of sales after approval of the drug in late 2013.”
$11B for one indication...in 2013!
Holeeeee schnikeees - CYDY puts that to shame.
Dr. J et. al. - bring us a BIG number por favor...
...and STAT, 'cuz patience is not my core competence.
(8)
(0)
